Cellenkos Inc., a Houston, Texas-based biotech company focused on developing transformative novel T regulatory (Treg) cell therapies to treat autoimmune and inflammatory disorders, closed a $15m Series A financing.
The round was led by BVCF Management Ltd.
Proceeds from this financing will be used to further its development on the Treg cell therapy platform to address high unmet needs in autoimmune and inflammatory disorders.
Founded by Simrit Parmar, MD. of the University of Texas MD Anderson Cancer Center and Golden Meditech Holdings Limited, Cellenkos is a clinical stage biotech company focused on the development and commercialization of transformative novel allogeneic Treg cell therapies to treat autoimmune and inflammatory disorders. Its proprietary CRANE™ platform allows to generate tissue directed, activated and enriched Treg cells that leverage cellular intelligence to seek, localize, proliferate and resolve tissue inflammation.
The company’s lead products include CK0802, a novel allogeneic cell therapy product consisting of lung homing Treg cells from umbilical cord blood units, for the treatment of Acute Respiratory Distress Syndrome (ARDS) and CK0804, novel bone marrow homing allogenic Treg subpopulation, for the treatment of Myelofibrosis. The company’s cord blood-derived Treg cell therapeutic platform is licensed from the University of Texas MD Anderson Cancer Center.
Cellenkos’ in-house cGMP facility allows for large-scale manufacturing where multiple doses can be generated from a single umbilical cord blood unit. These off-the-shelf allogeneic cell products are cryopreserved and are available on-demand for infusion at the point of care.